| Document |
Document Title |
|
WO/2024/054991A1 |
A non-naturally occurring protein dimer is provided and comprises two monomers that are each antagonists of the Na/K-ATPase-Src receptor complex. Each peptide monomer has an amino acid sequence of SEQ ID NO: 1 or a functional fragment or...
|
|
WO/2024/051641A1 |
The present invention provides an anti-EGFR and cMet bispecific chimeric antigen receptor and use thereof. Specifically, the present invention provides an immune cell expressing a first CAR and a second CAR, the first CAR targets a first...
|
|
WO/2024/050627A1 |
Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and/or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides ...
|
|
WO/2024/050648A1 |
Methods of treating a subject who has or is at risk of having a chemo-resistant tumor comprising a step of administering a pharmaceutical composition comprising a self-assembled polypeptide complex, which methods result in slowing, inhib...
|
|
WO/2024/054897A1 |
The inventors hypothesized that the induction of a multitude of neoantigens in tumor cells, through hundreds of thousands of RNA editing events, would render tumors more recognizable by the patient's own T cells and that this could serve...
|
|
WO/2024/051831A1 |
The present invention relates to a constitutive chimeric cytokine receptor, comprising an extracellular domain and a constitutively activated IL-7R mutant. The extracellular domain consists of an effector molecule capable of remodeling t...
|
|
WO/2024/046239A1 |
The present invention relates to a specific recombinant humanized monoclonal antibody targeting human GPRC5D and an application thereof, can be used in ELISA and flow detection methods, and can be used for diagnosis and treatment targeti...
|
|
WO/2024/046072A1 |
Disclosed are an immune cell having membrane-bound IL-21 (mbIL-21), and a preparation method therefor and a use thereof. Specifically, disclosed are mbIL-21 and a use thereof in immunotherapy. mbIL-21 can enhance the expansion capability...
|
|
WO/2024/046234A1 |
The present invention relates to an antibody that specifically binds to complement C5, and a fusion protein thereof. The present invention also relates to a polynucleotide, an expression vector, and a host cell that encode the antibody o...
|
|
WO/2024/049153A1 |
The present invention relates to a nanoparticle and a preparation method therefor, the nanoparticle comprising an amphiphilic peptide, which forms a micelle structure through self-assembly, and a target peptide (preferably, a water-solub...
|
|
WO/2024/048599A1 |
Provided is a highly stable and versatile protein-nucleic acid complex. This protein-nucleic acid complex comprises a nucleic acid molecule having uracil, a uracil DNA glycosylase domain covalently bound to the nucleic acid molecule, and...
|
|
WO/2024/048683A1 |
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...
|
|
WO/2024/046394A1 |
Provided are a TIGIT and OX40-based strengthened receptor (TIGIT/OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the strengthened receptor. Also provided is an im...
|
|
WO/2024/048050A1 |
According to the present disclosure, provided is a carrier peptide fragment having excellent cell membrane permeability. The disclosed carrier peptide fragment comprises an amino acid sequence represented by SEQ ID NO: 1, KKRTLRKSNRKKR, ...
|
|
WO/2024/045430A1 |
The present invention relates to the technical field of biological functions of proteins, and specifically relates to a polypeptide, a fused polymer protein and the use thereof. The polypeptide is selected from: (1) a polypeptide that ha...
|
|
WO/2024/048570A1 |
The present invention addresses the problem of providing a vaccine composition for nasal administration that is usable for preventing and treating hepatitis B, and a nasal administration system of the vaccine. Provided is a hepatitis B...
|
|
WO/2024/046404A1 |
A recombinant botulinum toxin and a preparation method therefor. By designing and optimizing the heavy chain and light chain sequences of the recombinant botulinum toxin, adding and cleaving protein tags will not introduce amino acid res...
|
|
WO/2024/046322A1 |
The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administe...
|
|
WO/2024/047162A1 |
The present invention relates in general to the field of medicine. More particularly, it relates to polypeptide conjugates, compositions and methods for promoting immune tolerance to the CRISPR-Cas (Clustered Regularly Interspaced Short ...
|
|
WO/2024/046301A1 |
The present disclosure provides a fusion protein comprising a TACI polypeptide and a use thereof, particularly a use for preventing or treating autoimmune diseases.
|
|
WO/2024/041618A1 |
The present invention relates to an engineered immune cell co-expressing CD40L. In particular, the engineered immune cell of the present invention is a T cell or an NK cell. According to the present invention, a CAR molecule containing t...
|
|
WO/2024/044547A1 |
Described herein are antibodies and immunoconjugates capable of targeting antigens within the kidney. The antibodies described herein generally a polypeptide, wherein the polypeptide comprises: an antigen-binding domain (e.g., immunoglob...
|
|
WO/2024/040681A1 |
The present invention relates to an uPAR-targeted third-generation chimeric antigen receptor, immune effector cells (e.g., T cells, NK cells) engineered to express the chimeric antigen receptor of the present invention, and a use of the ...
|
|
WO/2024/041236A1 |
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...
|
|
WO/2024/041477A1 |
Provided is use of a multi-domain fusion protein in the preparation of a medicament for treating or preventing tumors. The fusion protein comprises an anti-PD-L1 single-domain antibody fragment, a VEGF-antagonizing fragment and a TGF-β ...
|
|
WO/2024/044721A1 |
Embodiments of the present disclosure provide compositions and methods for injectable recombinant protein-based hydrogels for therapeutic delivery. Embodiments of the composition and methods comprise a recombinant protein, a cell consort...
|
|
WO/2024/044557A1 |
The present disclosure provides enveloped delivery vehicles (EDVs) comprising a nucleic acid-binding effector polypeptide, or a nucleic acid encoding the nucleic acid-binding effector polypeptide, where the EDV comprises a fusion polypep...
|
|
WO/2024/044574A1 |
The present disclosure provides methods for reducing ionizing radiation-induced damage of cells such as hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). The methods comprise introducing into HSCs and/or HPCs a f...
|
|
WO/2024/044726A1 |
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protei...
|
|
WO/2024/044572A1 |
Modified DNA-binding proteins are provided. DNA binding proteins of interest include fusion proteins having a zinc finger DNA binding polypeptide with an alpha-helix recognition domain configured to bind to a target nucleotide sequence i...
|
|
WO/2024/041579A1 |
Disclosed is a multi-specific antibody targeting CD40 and PD-L1, as well as its use in the treatment of diseases such as tumors.
|
|
WO/2024/037531A1 |
Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, ...
|
|
WO/2024/039683A1 |
Compositions and methods for therapeutic use of engineered myeloid cells are described. Methods for increasing therapeutic effectiveness of immune cells by use of an immune cell inhibitory agent prior to therapy is described. Effective u...
|
|
WO/2024/037322A1 |
Disclosed in the present invention are an IL-15 mutant-Fc/IL-15Rα subunit-Fc heterodimer and the use thereof. The heterodimeric protein comprises protein a and protein b, wherein the protein a comprises an IL-15 mutant and a first Fc mu...
|
|
WO/2024/038809A1 |
This fusion protein contains a plurality of receptor binding domains from parvovirus, wherein each receptor binding domain is tandemly linked with another such receptor binding domain, either directly or via a peptide linker.
|
|
WO/2024/038447A1 |
The present invention provides a chimeric polynucleotide comprising: a first nucleic acid sequence encoding a first polypeptide selected from: alpha S 1 casein, alpha S2 casein, and beta casein, a whey polypeptide, or a functional analog...
|
|
WO/2023/226921A9 |
The present invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and an application thereof. The bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; the extracellular antig...
|
|
WO/2024/037477A1 |
The present invention relates to a bispecific chimeric antigen receptor, and an immune cell, a preparation method, an application and a tumor treatment drug. Provided is a bispecific chimeric antigen receptor, the chimeric antigen recept...
|
|
WO/2024/037005A1 |
The present invention provides a human cytomegalovirus antigen epitope chimeric peptide and a use thereof. An amino acid sequence of the human cytomegalovirus antigen epitope chimeric peptide is selected from SEQ ID NO.1, SEQ ID NO.2, SE...
|
|
WO/2024/034200A1 |
Disclosed are a highly rigid peptide linker inserted between a transmembrane protein and an organelle transport signal, a fusion protein containing the same, and a localization method that includes inserting a peptide linker.
|
|
WO/2024/031187A1 |
There is provided a polynucleotide-modifying enzyme with a functional nuclease domain and a display domain. The functional nuclease domain comprises a nuclease catalytic pocket. The display domain comprises a peptidic recognition sequenc...
|
|
WO/2024/031181A1 |
Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (...
|
|
WO/2024/032454A1 |
Disclosed in the present invention is a long-acting abaloparatide compound. The long-acting compound of the present invention is used for preparing a pharmaceutical composition for treating diseases. Provided is a use of the pharmaceutic...
|
|
WO/2024/032468A1 |
The present invention relates to the field of molecular vaccinology. Provided is a recombinant multi-component SARS-CoV-2 trimer protein vaccine capable of inducing broad-spectrum neutralization activity. The components of a recombinant ...
|
|
WO/2024/033879A1 |
The present disclosure relates to modified cells, e.g., chimeric antigen receptor (CAR) T cells and/or exogenous T cell receptor (eTCR) cells, which have reduced in vivo immunogenicity, and the use thereof.
|
|
WO/2024/034619A1 |
According to an embodiment, the present disclosure provides a modified luciferase having improved luminescence intensity, and a use thereof. The present disclosure relates to a modified luciferase derived from a luminous mushroom, or a...
|
|
WO/2024/032617A1 |
The present invention relates to a heteromultimeric protein and a preparation method therefor. Specifically, the heteromultimeric protein comprises a first antibody heavy chain with the introduction of a T394K mutation with respect to S3...
|
|
WO/2024/027771A1 |
Provided in the present invention is an antibody fusion protein, which can specifically bind to an FAP protein and block a TGFβ signaling pathway. Further provided in the present invention are a nucleic acid molecule encoding the antibo...
|
|
WO/2024/027835A1 |
Provided is an antibody targeting EGFRvIII or an antigen-binding fragment thereof. Further provided are a CAR comprising the antigen-binding fragment targeting EGFRvIII, and treatment and detection use thereof.
|
|
WO/2024/030976A2 |
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of active agents conjugated to ligands for increased crossing of the blood brain barrier.
|
